Features
Get A Demo
Plans
Sign Up
Login
All Federal Contract IDV Awards
Help
Indefinite Delivery Contract HHSN271201700005I
Award Date
3/30/17
Last Date to Order
3/31/24
Overview
🤔 AI Insights
Buyer Personas
Industry Personas
Buyer Personas In this Market
Activity
6
Contract IDVs
Contract Awards
4
Transactions
6
Price Lists
Opportunity Stack
1
Funding Federal Agency
National Center for Advancing Translational Sciences
Contracting Federal Agency
National Institute on Drug Abuse
Awardee
Curia Global Inc.
Ultimate Awardee
Not listed
NAICS Category
325411 - Medicinal and Botanical Manufacturing
PSC Category
AN11 - Health R&D Services; Health Care Services; Basic Research
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
CRO Support for NCATS Drug Substance Development and Manufacture
Pricing Type
Order Dependent (IDV only)
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
CRO Support for NCATS Drug Substance Development and Manufacture
Master IDIQ
HHSN271201700005I
Indefinite Delivery Contract
4
Federal Contract Awards
Description
Update #1
Update #2
Update #3
CRO SUPPORT FOR DRUG SUBSTANCE DEVELOPMENT AND MANUFACTURE
Posted 3/30/17, 12:00 AM
Mod #
Description
Reason For Modification
Federal Obligation
(Click to sort descending)
Date
(Click to sort ascending)
P00005
PARENT IDIQ AWARD: CRO SUPPORT FOR NCATS DRUG SUBSTANCE DEVELOPMENT AND MANUFACTURE
Vendor DUNS or Name Change - Non-Novation
$0
3/29/22
P00004
EO14042 - PARENT IDIQ AWARD: CRO SUPPORT FOR NCATS DRUG SUBSTANCE DEVELOPMENT AND MANUFACTURE
Vendor DUNS or Name Change - Non-Novation
$0
10/21/21
P00003
CRO SUPPORT FOR DRUG SUBSTANCE DEVELOPMENT AND MANUFACTURE.
Other Administrative Action
$0
5/22/20
P00002
CRO SUPPORT FOR DRUG SUBSTANCE DEVELOPMENT AND MANUFACTURE
Other Administrative Action
($5k)
8/22/19
1
CRO SUPPORT FOR DRUG SUBSTANCE DEVELOPMENT AND MANUFACTURE
Other Administrative Action
$0
4/19/17
Name
Description
Awardee
Potential Value
(Click to sort descending)
Award Date
(Click to sort descending)
Completion Date
(Click to sort descending)
Updated At
(Click to sort descending)
Delivery Order HHSN271201700005I-75N95019F00088
This federal contract award is for the manufacture of 5.5-kg of cGMP mitragynine, a drug substance, by Curia Global Inc. (doing business as Amri). The award, with a ceiling value of $3,370,313.00, was issued by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the Department of Health and Human Services. This is a delivery order under the CRO Support for NCATS Drug Substance Development and Manufacture indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle. The contract has a period of performance through May 31, 2024 and does not have a set-aside designation. Curia Global is a leading contract development and manufacturing organization (CDMO) that provides a wide range of pharmaceutical research and development services to federal agencies, particularly the National Institutes of Health, through prime and subcontract awards.
Curia Global Inc.
$3.4m
8/22/19
5/31/24
8/2/24
Delivery Order HHSN271201700005I-75N95020F00002
This federal contract award to Curia Global Inc., doing business as Amri, is for the development of the drug substance (R)-VK4-116 dihydrochloride salt. The $1,804,267.88 cost-plus-fixed-fee contract was awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the Department of Health and Human Services. This contract is a delivery order under the NCATS' larger "CRO Support for NCATS Drug Substance Development and Manufacture" indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle. The award supports NCATS' drug substance development and manufacturing activities, with Curia providing a range of pharmaceutical research and development services, including medicinal chemistry, chemical development, analytical testing, and cGMP manufacturing. No set-aside designation was used for this contract.
Curia Global Inc.
$1.8m
9/21/20
3/31/26
12/17/24
Delivery Order HHSN271201700005I-75N95020F00001
This federal contract award to Curia Global Inc., doing business as Amri, is for the production of non-GMP (non-Good Manufacturing Practice) batches of the drug substances paynantheine, speciogynine, and speciociliatine salts. The contract, valued at $1,259,570.66, was awarded under the National Institute on Drug Abuse's (NIDA) indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle for Contract Research Organization (CRO) Support for NCATS Drug Substance Development and Manufacture. This award does not have a set-aside designation. Curia Global Inc. is a leading global contract development and manufacturing organization (CDMO) with extensive experience supporting various National Institutes of Health (NIH) institutes and other federal agencies through prime and subcontract awards, focusing on therapeutic development initiatives in areas such as neurology, infectious diseases, and substance abuse.
Curia Global Inc.
$1.3m
9/16/20
4/30/25
11/26/24
Delivery Order HHSN271201700005I-75N95023F00001
This federal contract award is for "CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC) DEVELOPMENT OF NCGC00413972 FOR PRECLINICAL SAFETY EVALUATION AND CLINICAL TRIAL" and was issued to Curia Global Inc., doing business as Amri. The contract, valued at $907,791.77, is a delivery order under the "CRO Support for NCATS Drug Substance Development and Manufacture" indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle. The National Center for Advancing Translational Sciences (NCATS), a civilian agency within the National Institutes of Health (NIH), awarded this firm fixed-price contract. The contract involves the development of a drug candidate, including medicinal chemistry, chemical development, analytical testing, and good manufacturing practices (GMP) production. Curia has significant experience supporting various NIH institutes through prime and subcontract awards for pharmaceutical research and development services. No set-aside designation was used for this award.
Curia Global Inc.
$907.8k
9/30/23
4/30/28
12/20/24
Name
Description
Solicitation Number
Federal Agency
Type
Posted Date
(Click to sort descending)
CRO Support for NCATS Drug Substance Development and Manufacture
Added: Mar 01, 2016 11:41 am This is not a Request for Proposals (RFP). This is a Pre-solicitation Announcement only. RFP No. N01TR-17-2001, titled "CRO Support for NCATS Drug Substance Development and Manufacture," will be issued via fedbizopps on or about March 17, 2016.The Division of Preclinical Innovation (DPI) at the National Center for Advancing Translational Sciences (NCATS) conducts translational research in the area of human therapeutics development and aims to move small molecule and biologic drug candidates forward in the drug development pipeline, at which point, DPI will hand off the drug candidate to external partner(s) to bring the novel therapy to patients.The overall goal of this proposed project is to support the DPI drug development program by contracting for Chemistry, Manufacturing, and Control services. Specifically, this proposed project is designed to ensure DPI receives Active Pharmaceutical Ingredients and formulated Drug Product of sufficient quality and quantity to support IND-enabling, pre-clinical, and clinical studies.To accomplish this goal, the Government plans to solicit proposals from offerors having in-house capability in one or more of the following technical areas: (1) Manufacture and Analysis of Small Molecules; (2) Manufacture and Analysis of Synthetic Peptides, Oligonucleotides, and Related Substances; and (3) Manufacture and Analysis of Biopharmaceuticals.The Government anticipates awarding multiple Indefinite Delivery/Indefinite Quantity (IDIQ) type contracts under this solicitation.The ultimate goal of DPI and this planned project is to bring new drugs to market. To this end, the Government will seek a Determination of Exceptional Circumstances (DEC) to deviate from the Federal Acquisition Regulation clauses at 52.227-11 Patent Rights and 52.227-14 Rights in Data. The deviated language will enable DPI contributors to retain control of their intellectual property, will be included in the RFP, and incorporated in any resultant contract. Prospective Offerors are advised that agreement to the terms of these FAR clauses deviations will be a condition for contract award.Based upon market research, the Government is not using the policies contained in Part 12, Acquisition of Commercial Items, in its solicitation for the described supplies or services. However, interested persons may identify to the Contracting Officer their interest and capability to satisfy the Government's requirement with a commercial item within 15 days of this notice.
N01TR-17-2001
Department of Health and Human Services National Institutes of Health
Award Notice 1/1
3/1/16, 11:41 AM